Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

4306studies shown

Showing 1,801-1,812 of 4,306

TerminatedEUCTR 2005-005501-28

Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Germany, Sweden
Sponsor: Pfizer AB
Condition: Schizophrenia

View study

CompletedEUCTR 2012-004504-35

The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Italy

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Italy
Sponsor: IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI
Condition: Schizophrenia

View study

CompletedEUCTR 2006-006642-34

Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: France, Germany, Italy, ...
Sponsor: Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Condition: Schizophrenia

View study

CompletedEUCTR 2007-001541-18

Triiodothyronine as an adjunct in treatment of acute schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Lithuania

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Lithuania
Sponsor: Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2013-001694-24

A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: France, United Kingdom, Belgium, ...
Sponsor: SUNOVION PHARMACEUTICALS INC.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2007-000577-38

A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Belgium, Bulgaria, Estonia, ...
Sponsor: Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2009-018038-12

A 26-week, multi-center, open-label, flexible dose, long-term safety trial of asenapine in adolescent subjects with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Romania
Sponsor: Schering-Plough Research Institute, a Division of Schering Corporation
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2004-002591-42

A pharmacoeconomic study conducted in parallel with clinical trial 10200, a 24-week double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients wit...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Spain
Sponsor: H.Lundbeck A/S
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2017-001739-38

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: United Kingdom
Sponsor: Takeda Development Centre Europe Ltd.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2018-002740-82

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: United Kingdom
Sponsor: Boehringer Ingelheim Limited
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2020-006062-36

A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Czechia, Estonia, Germany, ...
Sponsor: Newron Pharmaceuticals S.p.A.
Condition: Schizophrenia

View study

Recruitment unclearEUCTR 2009-017971-10

An 8-week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety trial of asenapine in adolescent subjects with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania

Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug

Countries: Romania
Sponsor: Schering-Plough Research Institute, a Division of Schering Corporation
Condition: Schizophrenia

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.